

DOJOLVI (triheptanoin)

Pre - PA Allowance

None

Prior-Approval Requirements

Diagnosis

Patient must have the following:

Long-chain fatty acid oxidation disorder (LC-FAOD)

AND ALL of the following:

- 1. Diagnosis of LC-FAOD has been molecularly confirmed
- 2. Patient will not be using Dojolvi with another medium-chain triglyceride (MCT) product
- 3. Prescriber agrees to monitor gastrointestinal (GI) adverse reactions and adjust the dose as needed
- 4. Patients using a feeding tube **only**: patient or caregiver will be advised to regularly inspect the feeding tube for proper functioning and integrity
- 5. NO pancreatic insufficiency

Prior - Approval Limits

Duration 12 months

Prior – Approval Renewal Requirements

Diagnosis

Patient must have the following:

Long-chain fatty acid oxidation disorder (LC-FAOD)

AND ALL of the following:

- 1. Patient has had an improvement in symptoms (e.g. less episodes of rhabdomyolysis)
- 2. Patient will not be using Dojolvi with another medium-chain triglyceride (MCT) product



DOJOLVI (triheptanoin)

- 3. Patients using a feeding tube **only**: patient or caregiver has been advised to regularly inspect the feeding tube for proper functioning and integrity
- 4. **NO** pancreatic insufficiency
- 5. NO unacceptable gastrointestinal (GI) toxicity

Prior - Approval Renewal Limits

Same as above